Quantisnow Logo
Dashboard

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $RCUS alert in real time by email

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March:

Leerink Global Healthcare Conference 2025

Date: Wednesday, March 12th, 2025

Location: Miami Beach, FL

Format: Fireside chat & 1x1 meetings

Time: 8:00 a.m. ET

Barclays 27th Annual Global Healthcare Conference

Date: Thursday, March 13th, 2025

Location: Miami Beach, FL

Format: Fireside chat & 1x1 meetings

Time: 8:00 a.m. ET

Live webcasts of the fireside chats and panel will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, A2a/A2b receptors, CD39 and AXL. For more information about Arcus Biosciences's clinical and preclinical programs, please visit www.arcusbio.com.

Investor Inquiries

Pia Eaves (Banerjee)

Head of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Maryam Bassiri

AD, Corporate Communications

(510) 406-8520

mbassiri@arcusbio.com

Get the next $RCUS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RCUS

DatePrice TargetRatingAnalyst
2/26/2025$18.00 → $24.00Neutral → Buy
H.C. Wainwright
10/21/2024$20.00Neutral
H.C. Wainwright
10/8/2024$29.00Overweight
Wells Fargo
11/18/2022$33.00Neutral
BofA Securities
10/11/2022$40.00Overweight
Morgan Stanley
11/19/2021$42.00 → $53.00Buy
Citigroup
11/19/2021$48.00 → $60.00Overweight
Barclays
11/18/2021$68.00 → $100.00Outperform
SVB Leerink
More analyst ratings

$RCUS
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 39,750 shares of the Company's common stock at an exercise price per share of $8.11, which was the closing price on April 23, 2025 and restricted stock units to acquire a total of 19,950 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

    New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The ASCO presentation will include a more mature data cut than that described in the abstract and will include safety and initial efficacy data for the 100mg casdatifan once-daily (QD) plus 60mg cabozantinib QD cohort Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing diff

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

    Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2025. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 762544. Participants may also register for the call online using the following link: https://events.q4inc.com/attendee

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RCUS
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RCUS
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$RCUS
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RCUS
 SEC Filings

See more

$RCUS
 Leadership Updates

Live Leadership Updates

See more

  • Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

    Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RCUS
 Financials

Live finance-specific insights

See more

  • Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

    New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The ASCO presentation will include a more mature data cut than that described in the abstract and will include safety and initial efficacy data for the 100mg casdatifan once-daily (QD) plus 60mg cabozantinib QD cohort Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing diff

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

    Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2025. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 762544. Participants may also register for the call online using the following link: https://events.q4inc.com/attendee

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

    A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily (BID) casdatifan monotherapy cohort of the Phase 1/1b ARC-20 study; mPFS was not yet reached for other cohorts Across all three monotherapy cohorts presented, casdatifan demonstrated improvements in the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date Arcus will host a conference call to discuss these data at 5:00 AM PT / 8:00 AM ET on Tuesday, February 18, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiate

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RCUS
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more